Oncology Venture - AP0010
APO010 is a novel, investigational systemic chemotherapeutic treatment targeting multiple myeloma,  a systemic malignancy in the blood that affects plasma cells.

This recombinant, soluble, hexameric fusion protein consists of three human Fas ligand (FasL) extracellular domains fused to the dimer-forming collagen domain of human adiponectin. It has potential pro-apoptotic and antineoplastic activities.
Therapeutic Target Annual Diagnoses (est.)
Multiple myeloma 160,000 (worldwide)

How it Works

The human immune system can kill cancer cells using a certain type of white blood cells called cytotoxic T lymphocytes (CTLs). One way CTLs kill cancer cells is programmed cell death (apoptosis). A Fas ligand (FasL) on the CTL binds to a death receptor (CD95) on the target cell. This triggers apoptosis. 

APO010 is synthesized as a mega FasL consisting of six FasL.  The target cell recognizes this as if it were a CTL that binds to the death receptor, triggering apoptosis of the target cell.

APO010 is expected to act in synergy with other cancer immunology agents such as ipilimumab and PD-1/PD-L1 inhibitors.

Clinical Trials

A Phase 1/2 clinical trial of APO010 was initiated in the second quarter of 2017 to identify, using the APO010 DRP, those Multiple Myeloma patients with the highest likelihood to benefit from treatment with APO010.

In a Phase 1 study in 25 patients with solid tumors, APO010 was well tolerated.

APO010 was found to be highly efficient in multiple myeloma in pre-clinical studies.

Oncology Venture Pipeline

Oncology Venture Pipeline


Validation of the APO010 DRP is underway in the ongoing Phase 1/2 clinical trial. 


Oncology Venture in-licensed APO010 from Onxeo (previously TopoTarget) in 2012. The drug candidate was originally designed by professor Jurg Tschopp in Lausanne and developed by Apoxis SA.